Trial reportThe journal of headache and pain2026
Efficacy and safety of transcutaneous supraorbital nerve stimulation versus topiramate for migraine prevention: a non-inferiority randomized trial.
Trial report in The journal of headache and pain, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02590939 (Multi-center, Double-blind, Randomized, Sham-controlled Trial on the Acute Treatment of Migraine With the Cefaly® Device), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Multi-center, Double-blind, Randomized, Sham-controlled Trial on the Acute Treatment of Migraine With the Cefaly® Device
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundMigraine remains a predominant neurological disorder that requires effective preventive therapies. Although topiramate is a well - recognized first - line pharmacotherapeutic approach, its use is often restricted by adverse reactions. Transcutaneous supraorbital nerve stimulation (tSNS) has emerged as a non - pharmacological alternative; however, its comparative efficacy remains unclear. This research aimed to directly compare the efficacy and safety of tSNS and topiramate in migraine prevention.
methodsIn this randomized, open - label, active - controlled trial, 232 adult migraineurs were randomly allocated to either tSNS or oral 25 mg topiramate for a 4 - week duration, followed by an 8 - week follow - up. The primary outcome was the proportion of responders. Secondary outcomes included changes such as monthly migraine days, severe headache days, days of acute medication use, and scores on the Headache Impact Test − 6. Non - inferiority testing with a pre - specified margin of 10% was also performed.
resultsThe tSNS group exhibited significantly lower responder rates than the low - dose topiramate group (20.6% vs. 33.9%), surpassing the 10% non - inferiority margin (p = 0.712, 95% CI: − 0.260 to − 0.007). Logistic regression affirmed the superior efficacy of 25 mg daily topiramate compared to the tSNS (adjusted OR = 2.32, 95% CI: 1.22–4.42, p = 0.011). When analyzing the secondary outcomes, the tSNS seemed to display efficacy in reducing severe headache days, while topiramate had a more pronounced effect on reducing moderate - severe headache days. In comparison with the tSNS, topiramate showed superior ability in reducing acute medication usage. The Headache Impact Test − 6 scores were comparable between the two groups. The tSNS presented significantly superior safety, with an adverse event rate of 4.3% as opposed to 22.4% in the topiramate group.
conclusionsThe tSNS seems to be less effective than even low - dose topiramate in achieving overall migraine prevention. However, the favorable safety profile of tSNS supports its consideration for medication - intolerant patients.
trial registrationNCT02590939: 2022/8/16.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.